Patent: 8,080,249
✉ Email this page to a colleague
Summary for Patent: 8,080,249
Title: | Methods to treating chronic obstructive pulmonary disease |
Abstract: | The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Enoiety. In accordance with the invention, COFD patients with sn elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioE the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroallergen. Anti-EgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy humanized murine monoclonal antibody, and/or Qmalizumab. |
Inventor(s): | Risk; Glifford G. (Marlborough, MA) |
Assignee: | |
Application Number: | 11/917,572 |
Patent Claims: | see list of patent claims |
Details for Patent 8,080,249
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | XOLAIR | omalizumab | For Injection | 103976 | 06/20/2003 | ⤷ Try a Trial | 2025-06-30 |
Genentech, Inc. | XOLAIR | omalizumab | Injection | 103976 | 09/28/2018 | ⤷ Try a Trial | 2025-06-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |